JUNE 13, 2025

Immunologic and Anaphylactoid Reactions in Ig Therapy

Mechanisms, severity, and clinical management

Amy E. Clarke, DNP, RN, IgCN^®

Chief Clinical Officer
Immunoglobulin National Society
Calabasas, California

Luba Sobolevsky, PharmD, IgCP^®

President/CEO
Immunoglobulin National Society
Calabasas, California

Immunoglobulin (Ig) therapy is essential for the management of immunodeficiencies, autoimmune diseases, and chronic inflammatory conditions. Whether administered intravenously (IVIG), or as subcutaneous (SCIG) or recombinant hyaluronidase-facilitated subcutaneous Ig (fSCIG) therapy, the

To read the full story, Log in or Sign up for a Free Account